NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as ...
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
After years of limping along, the GSK share price has leapt 11% in one month. But one of America's richest investors is ...
8h
GlobalData on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
12hon MSN
Enhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results